Kura Oncology (KURA) CSO sells 1,311 shares in tax sell-to-cover

Rhea-AI Filing Summary

Kura Oncology, Inc. Chief Scientific Officer Francis Burrows reported a small sale of company stock in connection with tax withholding. On January 27, 2026, he sold 1,311 shares of common stock at $8.4607 per share in a sell-to-cover transaction for taxes tied to the vesting of a restricted stock unit granted on January 26, 2022.

After this transaction, Burrows beneficially owns 32,424 shares of Kura Oncology common stock, held directly.

Insider Trade Summary

Net Seller: 1,311 shares ($11,092)

Net Sell 1 txn

Insider Burrows Francis

Role Chief Scientific Officer

Sold 1,311 shs ($11K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,311	$8.4607	$11K

Holdings After Transaction: Common Stock — 32,424 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burrows Francis

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/27/2026		S		1,311	D(1)	$8.4607	32,424	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22.

	Teresa Bair, Attorney-in-fact for Francis Burrows	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Kura Oncology (KURA) report for Francis Burrows?

Kura Oncology reported that Chief Scientific Officer Francis Burrows sold 1,311 shares of common stock. The sale occurred on January 27, 2026 at $8.4607 per share, as part of a sell-to-cover transaction for taxes related to a restricted stock unit vesting.

Why did Kura Oncology (KURA) CSO Francis Burrows sell 1,311 shares?

The 1,311 shares were sold to cover taxes due on the vesting of a restricted stock unit granted on January 26, 2022. This type of sell-to-cover transaction is commonly used so the insider does not need to provide separate cash to satisfy tax obligations.

How many Kura Oncology (KURA) shares does Francis Burrows own after the sale?

After the reported transaction, Chief Scientific Officer Francis Burrows beneficially owns 32,424 shares of Kura Oncology common stock. These shares are held directly in his name, according to the Form 4 insider trading disclosure filed for the January 27, 2026 transaction.

What was the price per share in the Kura Oncology (KURA) insider sale?

The reported sale by Chief Scientific Officer Francis Burrows was executed at a price of $8.4607 per share. This price applied to all 1,311 shares sold on January 27, 2026 as part of the tax-related sell-to-cover transaction tied to RSU vesting.

What role does Francis Burrows hold at Kura Oncology (KURA) in this Form 4?

In the Form 4 filing, Francis Burrows is identified as an officer of Kura Oncology, serving as Chief Scientific Officer. His position means his trades must be reported to the SEC, providing transparency into insider ownership and transactions in the company’s common stock.

Was the Kura Oncology (KURA) insider transaction a discretionary sale?

The filing describes the transaction as a sell-to-cover for taxes from vesting of a restricted stock unit. This indicates the sale was primarily to satisfy tax obligations arising from equity compensation, rather than a purely discretionary open-market sale by Francis Burrows.